Compare DG & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DG | WAT |
|---|---|---|
| Founded | 1939 | 1958 |
| Country | United States | United States |
| Employees | N/A | 7900 |
| Industry | Department/Specialty Retail Stores | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1B | 29.2B |
| IPO Year | 2008 | 1996 |
| Metric | DG | WAT |
|---|---|---|
| Price | $135.47 | $283.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 17 |
| Target Price | $139.80 | ★ $386.38 |
| AVG Volume (30 Days) | ★ 2.5M | 1.4M |
| Earning Date | 06-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.63% | N/A |
| EPS Growth | N/A | ★ 0.47 |
| EPS | 4.92 | ★ 10.76 |
| Revenue | ★ $40,612,308,000.00 | $3,165,286,000.00 |
| Revenue This Year | $8.06 | $104.66 |
| Revenue Next Year | $4.19 | $10.53 |
| P/E Ratio | $29.38 | ★ $27.66 |
| Revenue Growth | 4.96 | ★ 6.99 |
| 52 Week Low | $77.52 | $275.05 |
| 52 Week High | $158.23 | $414.15 |
| Indicator | DG | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 30.60 | 24.58 |
| Support Level | $132.57 | $281.33 |
| Resistance Level | $154.38 | $308.14 |
| Average True Range (ATR) | 4.61 | 9.04 |
| MACD | -1.90 | -1.01 |
| Stochastic Oscillator | 22.00 | 0.48 |
Since its beginning in 1939, Dollar General has grown to become the largest dollar store operator in the United States, with more than 20,000 small-box discount stores across 48 states. The firm generated $40 billion in fiscal 2024 sales. The retailer maintains a heavy concentration of stores in rural and low-income markets underserved by big-box retailers. It's 11,000 stock-keeping units, including 2,000 priced at $1 or less, span consumables (82% of sales), seasonal items (10%), home products (5%), and apparel (3%). More than 20% of sales are derived from private label.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.